Anthony Jaslowski, MD, FACP

Dr. Jaslowski was born in Chicago, Illinois. He received his B.S. degree from the United States Air Force Academy and attended medical school at the Loyola University Stritch School of Medicine in Chicago. He completed his internship residency and his hematology and oncology fellowship at Wilford Hall Medical Center at Lackland Air Force Base in Texas. He is board certified in hematology, medical oncology and internal medicine and is a Fellow of the American College of Physicians.

Dr. Jaslowski resides in Green Bay with his wife, Shelley, and their children.

“New cancer treatments continue to bring increasing promise. My goal is to ensure that my patients are given the very best choices to fight this disease.”

SERVICES:

  • Treatment of all cancer types
  • Treatment of adult blood disorders
  • National Cancer Institute (NCI) Community Oncology Research Program (NCORP) trial participant

MEDICAL SCHOOL:

  • Loyola University Stritch School of Medicine, Chicago, IL

RESIDENCY:

  • Wilford Hall Medical Center, Lackland Air Force Base, TX

FELLOWSHIP:

  • Hematology: Wilford Hall Medical Center, Lackland Air Force Base, TX
  • Medical Oncology: Wilford Hall Medical Center, Lackland Air Force Base, TX

BOARD CERTIFICATION:

  • Hematology
  • Medical Oncology
  • Internal Medicine

DISTINCTIONS:

  • Past military consultant to the Surgeon General for Hematology-Oncology
  • Twice awarded Humanitarian of the Year, Keesler Air Force Base, MS
  • Married, father of four children

STYLE OF PRACTICE:

Dr. Jaslowski is very focused on patient understanding and has a wonderful ability to simplify even the most complex information.
KEY TRAITS: Insightful, compassionate, expressive

 

  • Anthony's Blog Posts

    Presently, the state Senate is considering passing the bill on oral chemotherapy. The state Assembly last week passed the bill which would cap the amount of co-payment at $100 per ...

    The US Food and Drug Administration (FDA) approved ibrutininb in November 2013 for the treatment of relapsed mantle cell lymphoma. Ibrutinib is a new drug which was developed to specifically ...